A carregar...
Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients
BACKGROUND: Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis. First-line multikinase inhibitors like sorafenib and lenvatinib are poorly tolerated and have low response rates. Several clinical trials have shown tolerability and efficacy of immunotherapy in this setting. Th...
Na minha lista:
| Publicado no: | Fed Pract |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontline Medical Communications Inc.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7953859/ https://ncbi.nlm.nih.gov/pubmed/33716486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12788/fp.0061 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|